Apimeds Pharmaceuticals US (APUS) Cash from Investing Activities (2025)
Apimeds Pharmaceuticals US's (APUS) quarterly Cash from Investing Activities came in at -$10.0 million in Q4 2025, down 44374.01% quarter-over-quarter from -$22540.0 in Q3 2025.
Powered by 
Analysis
Apimeds Pharmaceuticals US (APUS) Cash from Investing Activities (2025) Analysis & Trends
Apimeds Pharmaceuticals US (APUS) has reported Cash from Investing Activities for 1 consecutive years, with -$10.0 million the latest figure, recorded in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.73 Bn | 197.74 Bn | 7.24 Bn | -569.00 Mn |
| 2 | Gilead Sciences | 180.92 Bn | 177.74 Bn | 6.22 Bn | -10.35 Bn |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn | -45.80 Mn |
| 4 | Regeneron Pharmaceuticals | 82.89 Bn | 74.90 Bn | 3.93 Bn | -92.70 Mn |
| 5 | Argenx Se | 61.41 Bn | 56.23 Bn | 1.37 Bn | - |
| 6 | Moderna | 53.99 Bn | 48.85 Bn | 52.00 Mn | 329.00 Mn |
| 7 | Alnylam Pharmaceuticals | 34.48 Bn | 31.18 Bn | 992.69 Mn | -363.46 Mn |
| 8 | Biogen | 31.15 Bn | 29.86 Bn | 1.96 Bn | -3.84 Bn |
| 9 | Roivant Sciences | 30.05 Bn | 30.05 Bn | 1.16 Mn | 281.26 Mn |
| 10 | Apimeds Pharmaceuticals US | 3.79 Mn | 3.79 Mn | - | - |